Biotech | December 13, 2021
Zydus to begin Phase II (a) clinical trial of ZYIL1 in Australia
It is a novel oral NLRP3 inflammasome inhibitor
It is a novel oral NLRP3 inflammasome inhibitor
The investment will establish additional capacity across the entire global value chain from manufacturing of active pharmaceutical ingredients (API) to assembly and packaging, with the vast majority being invested in API capacity
Next-generation sequencing (NGS) enables a better understanding of genetic mechanisms linked to specific diseases and is helping drive personalised healthcare
The company will provide recyclability services to brands with a final goal to help them move to fully recyclable packaging
KOREA PACK and concurrent event ICPI Week (Int’l Cosmetic and Pharmaceutical Industry Week) will be held as hybrid events in 2022
Over the next few years, Philips aims to double the number of its active cath labs in India with a special focus on improving accessibility to quality cardiac and neurovascular care in tier 2 and tier 3 cities
The group now has 325 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.
Results from the ongoing vodobatinib clinical study are being presented for the second consecutive year at the ASH annual meeting, underlining the promising potential of the drug for the treatment of heavily pre-treated CML
The company will donate 5000 nebulizers to primary health care centres in rural India
The company is focused on the development of novel treatments for RNA viruses
Subscribe To Our Newsletter & Stay Updated
